What is Biotangents?
Biotangents operates at the intersection of biotechnology and agricultural science, specializing in the development of next-generation molecular diagnostics tailored for the animal health sector. The company's core mission is to enhance livestock productivity, improve animal welfare standards, and bolster global food security through rapid, accurate, and accessible diagnostic solutions. By focusing on the specific needs of the livestock industry, Biotangents addresses the urgent requirement for sustainable farming practices that mitigate disease impact and optimize herd health management.
The firm's market position is defined by its ability to translate complex molecular data into actionable insights for veterinarians and farmers. This technical proficiency allows for the early detection of pathogens, thereby reducing reliance on broad-spectrum treatments and promoting more efficient resource utilization in large-scale agricultural operations.
How much funding has Biotangents raised?
Biotangents has raised a total of $4.4M across 3 funding rounds:
Unspecified
$1.8M
Debt
$1.9M
Unspecified
$743K
Unspecified (2019): $1.8M with participation from Kelvin Capital and Scottish Investment Bank
Debt (2022): $1.9M led by Innovate UK
Unspecified (2022): $743K supported by Kelvin Capital and Scottish Enterprise
Key Investors in Biotangents
Innovate UK
Innovate UK is a national innovation agency that provides grant-in-aid funding to support high-potential research and development projects across the United Kingdom.
Kelvin Capital
Kelvin Capital is a private investment firm focused on providing growth capital to early-stage and scaling technology companies with high market potential.
Scottish Investment Bank
The Scottish Investment Bank acts as the investment arm of Scottish Enterprise, providing financial support to businesses to stimulate economic growth and innovation.
What's next for Biotangents?
With the recent capital infusion, Biotangents is well-positioned to transition from its current development stage toward broader commercialization and market penetration. The strategic roadmap likely involves scaling manufacturing capabilities to meet the rising demand for point-of-care diagnostic tools in the livestock sector. Furthermore, the company is expected to leverage this investment to expand its research and development pipeline, potentially exploring new diagnostic markers that address emerging threats to food security.
As the firm matures, the focus will shift toward establishing deeper partnerships with global agricultural stakeholders and regulatory bodies. By maintaining its commitment to innovation, Biotangents aims to set a new benchmark for diagnostic precision in animal health, ensuring that its technological advancements contribute directly to the sustainability and resilience of the global food supply chain.
